Gilenya Comprehensive Study by Indication (Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Primary Progressive MS (PPMS), Secondary Progressive MS (SPMS)), Distribution (Hospital Dispensaries, Retail Pharmacies, Third Party Online Sales), End User (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2030

Gilenya Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.3%

Summary
Market Segments
Table of Content
List of Table & Figures
Players Profiled

Gilenya Market Scope

Multiple sclerosis (MS) is a neurological illness that affects the brain and spinal cord. The myelin sheath is harmed by MS. The phrase "myelin sheath" refers to the substance that covers and protects human nerve cells. This injury disrupts communication between the brain and the body, resulting in MS symptoms. MS can cause problems with thinking and memory, as well as visual abnormalities, body coordination and equilibrium issues, and muscular weakness. GILENYA is a sphingosine 1-phosphate receptor modulator that is used to treat individuals with relapsing forms of multiple sclerosis. It is used to minimise the frequency of clinical exacerbations and postpone the onset of physical impairment.

Attributes	Details
Study Period	2018-2030
Base Year	2023
Unit	Value (USD Million)
Key Companies Profiled	Novartis AG (Switzerland)
CAGR	6.3%

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Switzerland Players will contribute to the maximum growth of Global Gilenya market throughout the predicted period.

Novartis AG (Switzerland) are some of the key players that are part of study coverage.

About Approach

The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview

The study have segmented the market of Global Gilenya market by Type and Region with country level break-up.

On the basis of geography, the market of Gilenya has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies

In October 2023, Teva launched a generic version of Gilenya in the US, marking the first generic competitor to enter the market. This could impact future sales and revenue for the drug.
On 11th May, 2021 - Novartis Announced FDA Approval of its �Gilenya� as the First Disease-Modifying Therapy for Pediatric Relapsing Multiple Sclerosis. The Approval Targets a Significant Unmet Need for Younger Patients with Multiple Sclerosis (MS), Who Have More Frequent Relapses Than Adults with MS.

Influencing Trend:

Wider Acceptance by Regulatory Bodies and High Expenditure in Pharma R&D

Market Growth Drivers:

Prevalence of Multiple Sclerosis and Rising Geriatric Population

Challenges:

High Initial Investment

Restraints:

Side Effects and Adverse Reactions and lack of trained Professionals

Opportunities:

Increasing Demand Across Western Regions

Key Target Audience

Gilenya Manufactures, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Market Segments

Report Objectives / Segmentation Covered

By Indication

Clinically Isolated Syndrome (CIS)
Relapsing-Remitting MS (RRMS)
Primary Progressive MS (PPMS)
Secondary Progressive MS (SPMS)

By Distribution

Hospital Dispensaries
Retail Pharmacies
Third Party Online Sales

By End User

Pediatric
Adult
Geriatric

By Regions

South America
- Brazil
- Argentina
- Rest of South America
Asia Pacific
- China
- Japan
- India
- South Korea
- Taiwan
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- Italy
- United Kingdom
- Netherlands
- Rest of Europe
MEA
- Middle East
- Africa
North America
- United States
- Canada
- Mexico

Table of Content

List of Tables & Figures

List of Tables

List of Figures

Figure 1. Porters Five Forces
Figure 2. Supply/Value Chain
Figure 3. PESTEL analysis
Figure 4. Global Gilenya: by Indication USD Million (2018-2023)
Figure 5. Global Gilenya: by Distribution USD Million (2018-2023)
Figure 6. Global Gilenya: by End User USD Million (2018-2023)
Figure 7. South America Gilenya Share (%), by Country
Figure 8. Asia Pacific Gilenya Share (%), by Country
Figure 9. Europe Gilenya Share (%), by Country
Figure 10. MEA Gilenya Share (%), by Country
Figure 11. North America Gilenya Share (%), by Country
Figure 12. Global Gilenya share by Players 2023 (%)
Figure 13. BCG Matrix for key Companies
Figure 14. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
Figure 15. Novartis AG (Switzerland) Revenue: by Geography 2023
Figure 16. Global Gilenya: by Indication USD Million (2025-2030)
Figure 17. Global Gilenya: by Distribution USD Million (2025-2030)
Figure 18. Global Gilenya: by End User USD Million (2025-2030)
Figure 19. South America Gilenya Share (%), by Country
Figure 20. Asia Pacific Gilenya Share (%), by Country
Figure 21. Europe Gilenya Share (%), by Country
Figure 22. MEA Gilenya Share (%), by Country
Figure 23. North America Gilenya Share (%), by Country

Companies Mentioned

List of companies from research coverage that are profiled in the study

Novartis AG (Switzerland)

Select User Access Type

Single User
$ 3450
Corporate User
$ 6500

Key Highlights of Report

Feb 2024 213 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing

Check Discount Now

Global Gilenya Market Quantitative research analysis

Global Gilenya Market Qualitative Industry Analysis

DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?

"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Prevalence of Multiple Sclerosis
Rising Geriatric Population

Know More About Global Gilenya Market Report?

Have a Query? Click Here

Gilenya Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.3%

Report Objectives / Segmentation Covered

Talk to Our Experts

Want to Customize Study?

Frequently Asked Questions (FAQ):

What are the key segments playing vital role in Gilenya Market?

How big is the Gilenya Market?

What are the key driving factors for the growth of the Gilenya Market?

Know More About Global Gilenya Market Report?

Subscribe our newsletter now

Gilenya Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.3%

Report Objectives / Segmentation Covered

Talk to Our Experts

Want to Customize Study?

Frequently Asked Questions (FAQ):

What are the key segments playing vital role in Gilenya Market?

How big is the Gilenya Market?

What are the key driving factors for the growth of the Gilenya Market?

Know More About Global Gilenya Market Report?

Other Related Reports